News

FDA Commissioner Marty Makary said the agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost ...
The U.S. Food and Drug Administration has approved Bravecto Quantum, a new shot that protects dogs six months or older ...
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...
The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...
The letters, many of which were already available online, detail why the regulators initially declined to approve some drugs.
Fluralaner for extended-release injectable suspension (Bravecto Quantum) is also indicated for treatment of lone star tick in ...
On this week's episode of "The Readout LOUD": a closer look at the NIH’s grant-cutting legal playbook, FDA transparency ...
If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...
The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.
Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...
Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster product ...